Weight-loss drugs for children: Breakthrough or cause for caution?

A recent Danish study has demonstrated that semaglutide, a weight-loss drug, can help children with obesity lose weight and move below the obesity threshold. In a Phase III trial, 165 children aged 6 to under 12 years who received once-weekly semaglutide were found to have a 40.4% reduction in body mass index (BMI) compared to none in the placebo group after 68 weeks.

The STEP Young trial also incorporated lifestyle modification, with both groups adhering to a reduced-calorie diet and increased physical activity. However, the question remains whether pharmacological treatment should be initiated at such a young age, especially for children aged 6 to under 12. While the trial's results are promising, long-term safety, effects on nutrition and development, duration of treatment, affordability, and access are concerns.

Additionally, there is a risk of medicalizing obesity without addressing family and environmental factors that contribute to the issue. In India, where childhood obesity is on the rise, the availability and cost of semaglutide are significant barriers. The focus should be on comprehensive management, including lifestyle changes, nutrition, physical activity, mental health, and proper medical evaluation.